Ribavirin Concentrations, Laboratory Variables, and Clinical Outcomes During Treatment of Hepatitis C Infection with First Generation Direct-Acting Antivirals
| Autor: | J. M. Tredger, Phillip E. Morgan, Halina Michur, N. Heaton, Michael A. Heneghan, Ivana Carey, Nigel W. Brown, Kosh Agarwal |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Creatinine Univariate analysis Cirrhosis Multivariate analysis business.industry Ribavirin virus diseases Hepatitis C medicine.disease Gastroenterology digestive system diseases Telaprevir chemistry.chemical_compound chemistry Boceprevir Internal medicine medicine business medicine.drug |
| Zdroj: | European Journal of Clinical and Biomedical Sciences. 5:51 |
| ISSN: | 2575-4998 |
| DOI: | 10.11648/j.ejcbs.20190503.13 |
| Popis: | In treating hepatitis C infection, identification of reliable markers predicting virological non-response appear central to improving outcome and to prompting changes in dynamic treatment approaches. The interrelationship of ribavirin (RBV) concentrations and laboratory variables with clinical outcomes was evaluated in HCV patients treated with ribavirin, and with or without early direct acting antivirals (DAA). Correlations between RBV concentration, laboratory variables (haemoglobin, absolute lymphocyte, platelet and neutrophil counts, serum creatinine and hepatitis C viral load) and patients’ characteristics associated with sustained virological response (SVR) were investigated using multivariate analysis. The 76 patients studied all received interferon (INF) and RBV, with 37 additionally given Boceprevir or Telaprevir. Significant correlations were noted between week 1 RBV concentration and subsequent total exposure at weeks 2, 4 and 12 (P 30 g/L (week 8) experienced higher SVR rates (P 30 g/L. Six factors were predictive of SVR in univariate analysis, and three in multivariate analysis. There is an association between SVR and absolute lymphocyte count, IL-28B CC genotype, and HCV-RNA load fall at week 1 (>80 %) or week 2 (>90 %) in HCV patients treated with INF/RBV and early DAA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|